IMRN
Immuron Limited [IMRN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
IMRN Stock Summary
Top 10 Correlated Stocks
IMRN
In the News
IMRN Financial details
Company Rating
Sell
Market Cap
15.1M
Income
-6.76M
Revenue
4.77M
Book val./share
0.08
Cash/share
0.07
Dividend
-
Dividend %
-
Employees
6
Optionable
No
Shortable
Yes
Earnings
30 Aug 2024
P/E
-4.46
Forward P/E
-
PEG
-0.28
P/S
10.39
P/B
0.86
P/C
32.86
P/FCF
-7.2
Quick Ratio
8.75
Current Ratio
9.2
Debt / Equity
0
LT Debt / Equity
-
-
-
EPS (TTM)
-0.03
EPS next Y
-
EPS next Q
-
EPS this Y
45.61%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-12.36%
Revenue last 5Y
-5.44%
Revenue Q/Q
92.91%
EPS Q/Q
15.19%
-
-
-
-
SMA20
-
SMA50
50%
SMA100
50%
Inst Own
0.14%
Inst Trans
0.67%
ROA
-17%
ROE
-18%
ROC
-0.18%
Gross Margin
73%
Oper. Margin
-198%
Profit Margin
-210%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.481-5.96
52W High
-54%
52W Low
+130%
RSI
43
Rel Volume
0.02
Avg Volume
932.6K
Volume
19.99K
Perf Week
-19.3%
Perf Month
-39.47%
Perf Quarter
33.72%
Perf Half Y
21.05%
-
-
-
-
Beta
1.142
-
-
Volatility
0.11%, 0.18%
Prev Close
-6.12%
Price
2.3
Change
-6.12%
IMRN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-06-30
| Metric | History | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.02 | 0.01 | 0 | 0 | 0.01 | |
| Net income per share | -0.03 | -0.02 | -0.04 | -0.01 | -0.02 | |
| Operating cash flow per share | -0.01 | -0.02 | -0.02 | -0.01 | -0.01 | |
| Free cash flow per share | -0.01 | -0.02 | -0.02 | -0.01 | -0.01 | |
| Cash per share | 0.04 | 0.02 | 0.11 | 0.1 | 0.08 | |
| Book value per share | 0.05 | 0.03 | 0.12 | 0.1 | 0.09 | |
| Tangible book value per share | 0.05 | 0.03 | 0.12 | 0.1 | 0.09 | |
| Share holders equity per share | 0.05 | 0.03 | 0.12 | 0.1 | 0.09 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 600.39M | 1.9B | 1.44B | 714.36M | 695.13M | |
| Enterprise value | 595.27M | 1.89B | 1.41B | 692.46M | 678.15M | |
| P/E ratio | -129.26 | -652.53 | -170.89 | -275.7 | -183.58 | |
| Price to sales ratio | 251.48 | 752.59 | 9.84K | 933.57 | 385.17 | |
| POCF ratio | -333.81 | -602.24 | -351.86 | -280.31 | -267.85 | |
| PFCF ratio | -333.43 | -602.08 | -351.29 | -279.21 | -267.05 | |
| P/B Ratio | 81.67 | 335.84 | 55.42 | 30.82 | 35.44 | |
| PTB ratio | 81.67 | 335.84 | 55.42 | 30.82 | 35.44 | |
| EV to sales | 249.33 | 751.33 | 9.67K | 904.95 | 375.77 | |
| Enterprise value over EBITDA | -128.97 | -648.72 | -197.47 | -226.81 | -190.18 | |
| EV to operating cash flow | -330.96 | -601.23 | -345.72 | -271.71 | -261.31 | |
| EV to free cash flow | -330.59 | -601.07 | -345.16 | -270.65 | -260.53 | |
| Earnings yield | -0.01 | 0 | -0.01 | 0 | -0.01 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0 | 0.01 | 0 | 0.01 | 0.02 | |
| Debt to assets | 0 | 0.01 | 0 | 0.01 | 0.02 | |
| Net debt to EBITDA | 1.11 | 1.09 | 3.5 | 7.17 | 4.76 | |
| Current ratio | 5.59 | 8.54 | 22.96 | 15.75 | 9.2 | |
| Interest coverage | 0 | -134.85 | -522.76 | -504.11 | -369.75 | |
| Income quality | 0.39 | 1.08 | 0.49 | 0.98 | 0.69 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 2.08 | 1.26 | 41.68 | 4.54 | 2.3 | |
| Research and developement to revenue | 0.44 | 0.47 | 9.38 | 0.86 | 1.44 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | -0.05 | -0.01 | 0 | |
| Capex to depreciation | -0.39 | -0.02 | -0.15 | -0.24 | -0.16 | |
| Stock based compensation to revenue | 0.56 | -0.21 | 14.52 | 0.12 | 0.13 | |
| Graham number | 0.19 | 0.11 | 0.32 | 0.16 | 0.18 | |
| ROIC | -0.63 | -0.5 | -0.28 | -0.12 | -0.16 | |
| Return on tangible assets | -0.54 | -0.47 | -0.31 | -0.1 | -0.17 | |
| Graham Net | 0.03 | 0.02 | 0.11 | 0.09 | 0.08 | |
| Working capital | 5.49M | 3.89M | 24.63M | 22.17M | 18.19M | |
| Tangible asset value | 7.35M | 5.64M | 25.9M | 23.18M | 19.62M | |
| Net current asset value | 5.47M | 3.85M | 24.59M | 21.99M | 18.04M | |
| Invested capital | 0 | 0.01 | 0 | 0.01 | 0.02 | |
| Average receivables | 1.33M | 648.31K | 331.2K | 498.8K | 540.16K | |
| Average payables | 702.22K | 436.38K | 132.27K | 413.88K | 956.82K | |
| Average inventory | 521.12K | 671.02K | 545.11K | 309.56K | 583.27K | |
| Days sales outstanding | 148.13 | 47.49 | 838.05 | 316.2 | 84.42 | |
| Days payables outstanding | 391.11 | 83.53 | 763.95 | 1.09K | 878.53 | |
| Days of inventory on hand | 297.71 | 422.68 | 2.09K | 493.2 | 618.67 | |
| Receivables turnover | 2.46 | 7.69 | 0.44 | 1.15 | 4.32 | |
| Payables turnover | 0.93 | 4.37 | 0.48 | 0.34 | 0.42 | |
| Inventory turnover | 1.23 | 0.86 | 0.17 | 0.74 | 0.59 | |
| ROE | -0.63 | -0.51 | -0.32 | -0.11 | -0.19 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q2
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0.01 | 0.01 | |
| Net income per share | 0 | -0.01 | 0 | -0.01 | -0.01 | |
| Operating cash flow per share | 0 | 0 | 0 | -0.01 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | -0.01 | 0 | |
| Cash per share | 0.08 | 0.08 | 0.08 | 0.08 | 0.07 | |
| Book value per share | 0.09 | 0.09 | 0.09 | 0.09 | 0.08 | |
| Tangible book value per share | 0.09 | 0.09 | 0.09 | 0.09 | 0.08 | |
| Share holders equity per share | 0.09 | 0.09 | 0.09 | 0.09 | 0.08 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 724.07M | 695.14M | 637.71M | 695.13M | 628.52M | |
| Enterprise value | 705.59M | 676.86M | 620.55M | 678.15M | 613.47M | |
| P/E ratio | -183 | -87.84 | -176.34 | -96.11 | -75.79 | |
| Price to sales ratio | 2.48K | 1.19K | 1.04K | 569.28 | 266.82 | |
| POCF ratio | -1.46K | -737.59 | -795.55 | -449.61 | 0 | |
| PFCF ratio | -1.45K | -732.1 | -795.22 | -449.41 | 0 | |
| P/B Ratio | 34.05 | 32.69 | 32.51 | 35.44 | 35.86 | |
| PTB ratio | 34.05 | 32.69 | 32.51 | 35.44 | 35.86 | |
| EV to sales | 2.42K | 1.16K | 1.02K | 555.38 | 260.43 | |
| Enterprise value over EBITDA | -756.25 | -725.45 | -806.85 | -882.52 | -155.02 | |
| EV to operating cash flow | -1.42K | -718.19 | -774.15 | -438.63 | 0 | |
| EV to free cash flow | -1.41K | -712.85 | -773.82 | -438.44 | 0 | |
| Earnings yield | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0 | 0.01 | 0 | 0.02 | 0 | |
| Debt to assets | 0 | 0.01 | 0 | 0.02 | 0 | |
| Net debt to EBITDA | 19.8 | 19.59 | 22.31 | 22.08 | 3.8 | |
| Current ratio | 12.11 | 12.11 | 9.2 | 9.2 | 8.52 | |
| Interest coverage | 0 | -758.58 | 0 | -502.04 | -937.07 | |
| Income quality | 0.5 | 0.48 | 0.89 | 0.86 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 3.19 | 1.59 | 1.93 | 0.97 | 0 | |
| Research and developement to revenue | 2.61 | 2.61 | 0.88 | 0.88 | 1.13 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0.01 | 0 | 0 | 0 | |
| Capex to revenue | -0.01 | -0.01 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | -0.01 | -0.03 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0.19 | 0.09 | 0 | |
| Graham number | 0.1 | 0.14 | 0.09 | 0.12 | 0.13 | |
| ROIC | -0.04 | -0.15 | -0.04 | -0.11 | -0.19 | |
| Return on tangible assets | -0.04 | -0.09 | -0.04 | -0.08 | -0.1 | |
| Graham Net | 0.08 | 0.08 | 0.07 | 0.08 | 0.07 | |
| Working capital | 18.65M | 18.65M | 18.19M | 18.19M | 16.72M | |
| Tangible asset value | 21.26M | 21.26M | 19.62M | 19.62M | 17.53M | |
| Net current asset value | 18.49M | 18.49M | 18.04M | 18.04M | 16.59M | |
| Invested capital | 0 | 0.01 | 0 | 0.02 | 0 | |
| Average receivables | 436.15K | 276.73K | 181.54K | 218.22K | 0 | |
| Average payables | 421.28K | 121.7K | 456.31K | 991.84K | 0 | |
| Average inventory | 411.11K | 495.64K | 667.81K | 839.97K | 0 | |
| Days sales outstanding | 64.58 | 53.05 | 2.81 | 30.77 | 21.37 | |
| Days payables outstanding | 140.67 | 70.33 | 1.56K | 315.89 | 193.29 | |
| Days of inventory on hand | 572.9 | 286.45 | 1.66K | 222.45 | 188.04 | |
| Receivables turnover | 1.39 | 1.7 | 32.08 | 2.93 | 4.21 | |
| Payables turnover | 0.64 | 1.28 | 0.06 | 0.28 | 0.47 | |
| Inventory turnover | 0.16 | 0.31 | 0.05 | 0.4 | 0.48 | |
| ROE | -0.05 | -0.09 | -0.05 | -0.09 | -0.12 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
IMRN Frequently Asked Questions
What is Immuron Limited stock symbol ?
Immuron Limited is a AU stock , located in Carlton of Vic and trading under the symbol IMRN
What is Immuron Limited stock quote today ?
Immuron Limited stock price is $2.3 today.
Is Immuron Limited stock public?
Yes, Immuron Limited is a publicly traded company.
Company Profile
- Volume Average 932.6K
- Market Capitalization 15.1M
- Employee 6
- CEO Mr. Steven George Lydeamore CPA, M.B.A.
- Headquarters Carlton,VIC,AU
- IPO Date 2017-06-09
-
Website
https://www.immuron.com.au 
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.
